Clene Inc.
NASDAQ:CLNN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clene Inc.
NASDAQ:CLNN
|
US |
|
PharmaBlock Sciences Nanjing Inc
SZSE:300725
|
CN |
|
G
|
GIC Housing Finance Ltd
NSE:GICHSGFIN
|
IN |
|
K
|
Koninklijke Philips NV
MIL:PHIA
|
NL |
|
Khaitan (India) Ltd
NSE:KHAITANLTD
|
IN |
|
B
|
Bersama Mencapai Puncak PT Tbk
IDX:BAIK
|
ID |
|
Torq Resources Inc
XTSX:TORQ
|
CA |
|
A
|
Activision Blizzard Inc
LSE:0H8X
|
US |
|
Jiangsu Huaxin New Material Co Ltd
SZSE:300717
|
CN |
|
IMAX China Holding Inc
HKEX:1970
|
CN |
|
C
|
CAB Cakaran Corporation Bhd
KLSE:CARLSBG
|
MY |
|
Europap Tezol Kagit Sanayi Ve Ticaret AS
IST:TEZOL.E
|
TR |
|
H
|
Hainan Haiyao Co Ltd
SZSE:000566
|
CN |
Clene Inc.
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah and currently employs 95 full-time employees. The company went IPO on 2018-08-27. The firm is focused on the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure and neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is being evaluated in a Phase III registration trial in amyotrophic lateral sclerosis (ALS) and a Phase II trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). The firm has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah and currently employs 95 full-time employees. The company went IPO on 2018-08-27. The firm is focused on the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure and neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is being evaluated in a Phase III registration trial in amyotrophic lateral sclerosis (ALS) and a Phase II trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). The firm has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.
